At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States
In Brief
A Phase 2 clinical trial evaluating AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, and 1 other intervention for Primary Open Angle Glaucoma or Ocular Hypertension. Completed, enrolled 42 participants across 40 sites.
Detailed Summary
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
Study Details
Timeline
Interventions
Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Administered to each eye, once daily (QD) in the evening (PM) for 28 days